

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>LILLY ELI &amp; CO</u>			2. Date of Event Requiring Statement (Month/Day/Year) 04/06/2016		3. Issuer Name and Ticker or Trading Symbol <u>Aeglea BioTherapeutics, Inc. [ AGLE ]</u>		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____			5. If Amendment, Date of Original Filed (Month/Day/Year) 04/06/2016	
(Street) INDIANAPOLIS IN 46285						6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City)	(State)	(Zip)					

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	57,619	I	by fund <sup>(1)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series A Preferred Stock	(2)	(2)	Common Stock 890,476	0.0 <sup>(2)</sup>	I	by fund <sup>(1)</sup>
Series B Preferred Stock	(2)	(2)	Common Stock 1,120,448	0.0 <sup>(2)</sup>	I	by fund <sup>(1)</sup>

1. Name and Address of Reporting Person* <u>LILLY ELI &amp; CO</u>		
(Last)	(First)	(Middle)
LILLY CORPORATE CENTER		
(Street) INDIANAPOLIS IN 46285		
(City)	(State)	(Zip)
1. Name and Address of Reporting Person* <u>Lilly Ventures Fund I LLC</u>		
(Last)	(First)	(Middle)
115 W. WASHINGTON STREET SUITE 1680 SOUTH		
(Street) INDIANAPOLIS IN 46204		
(City)	(State)	(Zip)
1. Name and Address of Reporting Person* <u>Shanafelt Armen</u>		
(Last)	(First)	(Middle)
C/O LILLY VENTURES 115 W. WASHINGTON STREET, STE 1680 SOUTH		
(Street) INDIANAPOLIS IN 46204		
(City)	(State)	(Zip)

**Explanation of Responses:**

- These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.
- Each share of Series A Preferred Stock and Series B Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.

**Remarks:**

This Form is being amended to include Eli Lilly and Company's beneficial ownership of the shares reported in the Forms 3 separately filed by Lilly Ventures Fund I LLC and Shanafelt Armen on April 6, 2016.

Tiffany R. Benjamin, Authorized Person  
authorization on file

04/14/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Lilly Ventures Fund I, LLC  
115 West Washington Street  
Suite 1680-South  
Indianapolis, Indiana 46204

Securities and Exchange Commission  
Washington, D.C. 20549

Authorization Regarding Reporting Forms

I hereby authorize and designate the following persons to sign and file with the Commission on behalf of Lilly Ventures Fund I, LLC Forms relating to Section 16 and

James B. Lootens, Lilly Corporate Center, Indianapolis, Indiana

Bronwen Mantlo, Lilly Corporate Center, Indianapolis, Indiana

Tiffany R. Benjamin, Lilly Corporate Center, Indianapolis, Indiana

Eric M. Zinn, Lilly Corporate Center, Indianapolis, Indiana

This authorization and designation shall remain in effect until a written revocation is signed by me and provided to the Commission.

April 14, 2016

/s/ S. Edward Torres on behalf of Lilly Ventures Fund I, LLC

Shanafelt Armen  
115 West Washington Street  
Suite 1680-South  
Indianapolis, Indiana 46204

Securities and Exchange Commission  
Washington, D.C. 20549

Authorization Regarding Reporting Forms

I hereby authorize and designate the following persons to sign and file with the Commission on my behalf Forms relating to Section 16 and Schedule 13D or 13G of the

James B. Lootens, Lilly Corporate Center, Indianapolis, Indiana

Bronwen Mantlo, Lilly Corporate Center, Indianapolis, Indiana

Tiffany R. Benjamin, Lilly Corporate Center, Indianapolis, Indiana

Eric M. Zinn, Lilly Corporate Center, Indianapolis, Indiana

This authorization and designation shall remain in effect until a written revocation is signed by me and provided to the Commission.

April 14, 2016

/s/ Shanafelt Armen

S. Edward Torres  
115 West Washington Street  
Suite 1680-South  
Indianapolis, Indiana 46204

Securities and Exchange Commission  
Washington, D.C. 20549

Authorization Regarding Reporting Forms

I hereby authorize and designate the following persons to sign and file with the Commission on my behalf Forms relating to Section 16 and Schedule 13D or 13G of the

James B. Lootens, Lilly Corporate Center, Indianapolis, Indiana

Bronwen Mantlo, Lilly Corporate Center, Indianapolis, Indiana

Tiffany R. Benjamin, Lilly Corporate Center, Indianapolis, Indiana

Eric M. Zinn, Lilly Corporate Center, Indianapolis, Indiana

This authorization and designation shall remain in effect until a written revocation is signed by me and provided to the Commission.

April 14, 2016

/s/ S. Edward Torres